

Children’s Mercy Research Institute
Big Slick Auditorium
The Zebra Summit is a two-day conference bringing together patients, families, researchers, and clinicians who understand the rare journey firsthand.
This inaugural event is more than a conference, it’s the start of a community. Connect with other rare patients and families, hear directly from leading rare disease researchers and clinicians, and be part of building a center of gravity for rare disease and rare cancer care and innovation right here in our region.
This meeting is for the Rare KC Foundation Alliance, a group of key nonprofit rare disease foundations serving the region.
If you did not receive an invitation but would like to be considered for participation, please contact Brooke at Brooke@RareKC.org.
Location: Cinderblock, 10 E 18th Ave, North Kansas City, MO 64116
Speakers:
Kim Stanley, Braden’s Hope for Childhood Cancer
John Perry, PhD, Children’s Mercy
From Diagnostic Odyssey to Diagnostic Opportunity: Using Patient Perspective to shape Newborn Screening
The diagnostic odyssey is often measured in uncertainty, unanswered questions, and time. My family experienced this firsthand when my younger brother was diagnosed with early infantile Krabbe disease, a condition not included on our state’s newborn screening panel at the time. His story became the catalyst for our family’s rare-disease advocacy. Two decades later, I oversee various state newborn screening programs, bringing a family perspective to the systems I once hoped would have identified my brother’s condition sooner. This presentation will explore how patient and family experiences can shape newborn screening systems, from decisions about which conditions to include, to how results are communicated, when and by whom families receive information, and how condition-specific educational resources are developed.
Genomic Answers First (GA1): DNA-sequencing Augmenting All Subspecialty Care
Children’s Mercy is a leader in pediatric genomics. Its Genomic Answers for Kids (GA4K) program uses advanced genome sequencing to expand genetic testing and feeds into CMH Xetabase, a health system-wide repository containing genomic and structured symptom data from 25,000 individuals enrolled through GA4K or clinical sequencing. This uniquely organized pediatric resource has focused primarily on rare-disease enrollment and discovery. In contrast, larger adult EHR-linked resources have generated extensive research demonstrating the preventive and precision-medicine potential of integrated genomic and health data. To date, population level pediatric efforts have largely focused on newborn sequencing to supplement screening, which limit sequencing to severe, treatable conditions presenting at birth and identify actionable diagnoses in ~1.5% of newborns. However, genomics could influence care throughout childhood, especially in healthcare-based populations enriched for clinically relevant findings. To our knowledge, no health system has established comprehensive pediatric healthcare population-based genomic sequencing. Our new program, Genomic Answers First (GA1) brings highly efficient genome sequencing to the front door of subspecialty care at CMH. We will integrate genomic and EHR data in a large database to investigate genome-based precision medicine across pediatric care.GA1 provides a model for advanced genome testing scalable to impact entire health systems.
From Bedside to Bench
Advances in rare disease research are creating new possibilities for treatment. Translating these advances into meaningful benefits requires connecting scientific discovery with clinical care and the priorities of patients and families.
This presentation will explore therapeutic strategies for rare and ultra-rare diseases, including gene therapy, RNA-based approaches, and drug repurposing. Drawing on examples from the broader field and our experience at the University of Missouri’s Center for Translational Neurogenetics, we will discuss how disease biology guides treatment selection and how patient-derived cells, animal models, and clinical observations inform therapeutic development.
The discussion will connect these scientific foundations with the questions that matter across research and care: who might benefit, when to intervene, how to evaluate safety, and which outcomes reflect meaningful improvements in everyday life. Lessons from successful programs and setbacks will illustrate the opportunities and limitations of emerging therapies, alongside the importance of multidisciplinary care and long-term follow-up.
Throughout, we will highlight how partnerships among researchers, physicians, families, and advocacy organizations shape research priorities and help build a path from a genetic diagnosis toward potential treatment.
From One-Off to Off-the-Shelf: Why Making Viral Vectors Matters for Rare Disease
Most gene therapies for rare diseases depend on a viral vector, a modified virus that delivers a functional gene into a patient’s cells. Making these vectors is slow and expensive, and today almost every product needs its own manufacturing process. That cost falls hardest on diseases with small patient populations. This talk explains in plain terms what a viral vector is, what it can and cannot do today, and why manufacturing is one of the largest barriers between a promising therapy and the patients who need it. It then describes how the NIIMBL Viral Vector Program, a public-private effort, is working toward a common manufacturing platform for AAV vectors: a shared starting process, openly available guidance and data, and a network of sites capable of running it. It closes with what a platform could mean for rare disease programs and where the hard problems remain.
They Told Me Not to Google It: What a Diagnosis Can’t Prepare You For
Rare disease care often centers on what a diagnosis means for the patient. But what does it mean for the parent who becomes a full-time caregiver, the sibling whose family life changes, or the household trying to function through another hospitalization? As the parent of a child with an ultra-rare genetic condition and profound medical complexity, I have learned that the most difficult parts of this journey are often the ones no one prepares you for, and that caregiver well-being depends on more than emotional resilience alone.
Through candid reflections on my family’s experience, I will explore the intersection of medical complexity, caregiver mental health, and the everyday practical needs that can make an overwhelming life more manageable. I will share the moments of unexpected support that shaped my understanding of respite and led me to found RESTkc, a nonprofit providing practical assistance and caregiver well-being support to families of children with medical complexities.
Don’t Wait Your Turn. Take It! How to Create More Order When Health and Care Feel Uncertain
You can’t control the diagnosis. You can’t control every outcome. And getting healthcare to coordinate around you can take enormous effort. The hard truth is, no one’s coming.
Don’t wait your turn. Take it! Create more order around what you can influence, take more agency in your care, lighten the mental load, carry less in your head, and build more confidence and peace of mind even when uncertainty remains. This talk will share practical ways patients and families can create more clarity, feel better prepared for what comes next, reduce the fear of missing something important, make it easier for others to step in and help, and use tools, including AI, to carry less of the coordination burden themselves. The goal is simple: build repeatable systems that make care more manageable, free up mental space, and maybe even make room for the nap you’ve been owed for years.
A Maternal Genetic Change Provides a Protective Uterine Environment against Adverse Developmental Outcomes
A Protective Pregnancy Environment: How a Mother’s Genetics Can Change Developmental Outcomes
Rare genetic conditions can affect children differently, even when they carry the same disease-associated genetic change. Our research asks whether the environment within a mother’s uterus can help explain these differences. In mice, we found that mothers with only one functional copy of a gene called THM1 created a uterine environment that protected genetically at-risk embryos from cleft palate—even more effectively than the typical maternal environment. This protection came from the environment of the womb and was associated with improved signaling involving nutrients such as folate and vitamin B12. The same maternal genetic difference also protected embryos from developmental abnormalities caused by exposure to “forever chemicals,” including PFOA, a type of PFAS. Remarkably, we found evidence suggesting that this protective effect may also occur in people. By understanding how this maternal environment naturally protects development, we hope to identify nutrients or biological pathways that could one day be used to reduce the risk of birth defects.
Identification and Analysis of Repurposed Therapeutics for WARS2 Deficiency
Patients with WARS2 Deficiency face severe progressive neurological decline, including seizures and movement defects, with no curative treatment options. Our goal was to identify drugs that improve these symptoms. We model this disorder using Drosophila melanogaster, a fruit fly, where the flies with WARS2 deficiency solely in their eyes have decreased eye size. Using this model, we tested 1,520 repurposed therapeutics for their ability to increase the flies’ eye size and therefore rescue WARS2 deficiency. This “drug repurposing” approach uses existing FDA/EMA-approved drugs in a new context, allowing for potentially faster transition of treatments to patients. We identified 72 drugs that rescued our model, with antibiotics emerging as the top-performing drug class. To extend our findings, we generated a movement model where flies have WARS2 deficiency solely in their muscles, resulting in decreased climbing ability, similar to the movement defects patients experience. Using this model, we raised flies on drug-containing food and evaluated climbing ability. One antibiotic in particular demonstrated improved climbing, consistent with results from the eye model. Furthermore, this antibiotic also rescued a model of MARS2 Deficiency – a related disorder. These findings demonstrate that select antibiotics may serve as promising therapeutic candidates for WARS2 deficiency and related disorders.
What SPECC1L Can Teach Us About Brain Development and Disease Severity
SPECC1L-related syndrome is a rare genetic condition that can affect how the face, brain, and other parts of the body develop. Some children with changes in SPECC1L develop enlarged fluid spaces in the brain, called ventriculomegaly. In severe cases, this can lead to hydrocephalus, in which too much fluid builds up in the brain and may require surgery. Our research asks why this occurs. We found that SPECC1L is important for the development of the choroid plexus, a tissue in the brain that produces the fluid surrounding the brain and helps control what enters that fluid from the blood. In mice without Specc1l, the choroid plexus developed abnormally and the barrier between the blood and brain fluid became leaky. These mice also developed enlarged brain ventricles. We also found that the severity of these problems depends on the animals’ genetic background. This suggests that other genes can influence the effects of SPECC1L alteration and may help explain why people with the same rare genetic condition can experience very different symptoms. By understanding which genes and biological processes affect disease severity, we hope to improve our ability to predict outcomes and eventually identify better ways to prevent or treat complications.
Beyond Convention- Creative Collaboration to Obtain Genetic Testing for Children in Rural Populations
University of Missouri Research Reactor (MURR)
The University of Missouri Research Reactor (MURR), the most powerful reactor at a university in the United States, is a destination for researchers in the exploration of nuclear science. MURR supports research in life, social, and material sciences, and produces life-saving medical isotopes. Operating 52 weeks per year, MURR is the only producer of multiple isotopes used in the fight against cancer, impacting more than 1,000,000 patients each year. Research at MURR also impacts technologies in new energy, communication, transportation, and archaeology. MURR is now 60 years old and facing capacity challenges, and the university has launched the NextGen MURR project, which is an ambitious effort to build the first new research in the United States in 40 years. The new reactor, planned to be located in Columbia, Missouri at the university’s Discovery Ridge research park, will be larger and more powerful than MURR. It will serve the nation’s needs for nuclear research and isotope production for generations to come and serve as an economic development driver in the region.
Precision Medicine Targeting p53 Deficiency in Rare Pediatric Bone Cancer Osteosarcoma
Osteosarcoma, a rare pediatric bone cancer, often harbors defects in a gene called p53, the most commonly altered gene in human cancers. Normally, p53 protects cells from becoming cancerous. We discovered a treatment strategy that selectively causes p53-deficient cancer cells to stop dividing and die while sparing healthy cells by combining a drug that causes oxidative damage with a drug that blocks DNA repair. This approach showed strong anti-cancer activity against p53-deficient tumors. Because these drugs are either FDA-approved or in clinical development, this strategy could be rapidly advanced into clinical trials for patients with osteosarcoma and other p53-deficient cancers.
When Rare Becomes Personal One Family’s Journey, the Power of Community, and the Hope Behind Research
When a rare disease enters your life, everything changes. What once seemed unimaginable becomes your reality, and the search for answers takes on an entirely new meaning. For Kim Stanley, that journey began when her young daughter, Callyn, was diagnosed with retinoblastoma, a rare childhood eye cancer. Through treatment, relapse, and years of uncertainty, Kim experienced firsthand the extraordinary impact of medical innovation, the power of community, compassionate care, and the people who dedicate their lives to finding answers. Today, as President and Executive Director of Braden’s Hope for Childhood Cancer, Kim brings that deeply personal perspective to her work advancing childhood cancer research. In this heartfelt keynote, Kim shares how her family’s journey reshaped her understanding of hope, the importance of connection, and the power of turning personal experience into purpose. Her story offers a reminder that behind every diagnosis is a family, behind every scientific discovery is possibility, and behind meaningful progress is a community willing to work together. Because when rare becomes personal, hope anchors the soul and becomes a shared responsibility.
$15,000
$10,000
$5,000
$3,000


























